
Professor Sir Christopher Evans joins ReNeuron board
pharmafile | August 21, 2013 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ReNeuron, Sir Chirs Evans
Professor Sir Christopher Evans OBE, Europe’s most successful biotech entrepreneur, will be joining the board of ReNeuron Group as a non-executive director.
ReNeuron, which is relocating to Wales from Guildford, Surrey, is currently conducting the world’s first stem cell trial.
His appointment has been prompted by Sir Chris’s purchase of 24 million shares in the company (£600,000 at the placing price). Other associates of Sir Chris have also purchased a total of 9.6 million shares.
Sir Chris Evans commented: “I have been intimately involved with the creation and development of this company for the last 13 years. I have always been convinced of the compelling scientific case behind it and this continues to be confirmed by the results of the clinical trials to date.
“Now that we have secured this substantial financing for the company through to the critical clinical endpoints for all the product pipelines I am totally confident that we can ultimately drive this company to secure highly profitable partnerships or a substantive trade sale within the next three to four years.”
Related Content

ReNeuron’s stem cell therapy improves motor function in stroke study
ReNeuron, a UK-based biotechnology company, posted results of its experimental stem cell therapy for patients …

UK is the go-to place for developing medicines
The BioIndustry Association (BIA) has said that the UK is clearly the must-go-to location for …
ReNeuron relocates to Wales
The Welsh government is to fork out a £7.8 million grant package to get English …






